This HTML5 document contains 25 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB08888/identifier/national-drug-code-directory/
n8http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n7http://www.drugs.com/
n9http://www.rxlist.com/
n18http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB08888/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n16http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB08888/identifier/kegg-drug/
n13http://linked.opendata.cz/resource/drugbank/drug/DB08888/identifier/drugbank/
n5http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08888
rdf:type
n3:Drug
n3:description
Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.
n3:dosage
n15:271B5AD9-363D-11E5-9242-09173F13E4C5 n15:271B5ADA-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# FDA label
n3:group
approved
n3:indication
Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
owl:sameAs
n18:DB08888
dcterms:title
Ocriplasmin
adms:identifier
n11:24856-001-00 n12:Ocriplasmin n13:DB08888 n14:D09646
n3:mechanismOfAction
Ocriplasmin has proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (VRI) (e.g. laminin, fibronectin and collagen), thereby dissolving the protein matrix responsible for the vitreomacular adhesion (VMA).
n3:toxicity
The most commonly reported reactions (≥ 5%) in patients treated with ocriplasmin were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.
n4:hasAHFSCode
n8:52-92
foaf:page
n7:jetrea.html n9:jetrea-drug.htm
n3:Molecular-Formula
n16:271B5ADC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n16:271B5ADB-363D-11E5-9242-09173F13E4C5
n4:hasATCCode
n5:S01XA22
n3:absorption
Because of the small dose administered (0.125 mg), ocriplasmin is not expected to be in the systemic circulation following injection. Within 30 minutes after injection, levels of ocriplasmin in the vitreous are 12 mcg/mL. 24 hours after injection, levels in the virtreous are 0.5 mcg/mL
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
1048016-9-6
n3:category